“Monotherapy Group Endpoint” Added Before Trial Completion

It has been confirmed that the “monotherapy group endpoint” that AriBio cited as evidence of the success of the global Phase 3 trial of its oral dementia drug candidate AR1001 was not included in the clinical trial plan initially registered. Under the original design, the trial could be considered successful only if the drug worked in the overall patient population. During the trial, however, an additional criterion was added so that it could also be deemed successful if the drug worked in only some patients.


AriBio recently announced that AR1001 had succeeded in its Phase 3 trial, reporting that it had demonstrated efficacy in only some patient groups and not in the overall population. Under the original criteria, the trial would have been a failure, but the added criterion allowed the company to describe it as a success. Observers say this could become a factor in the drug’s future U.S. Food and Drug Administration (FDA) approval process.


According to ClinicalTrials.gov, the global clinical trial registration site operated by the U.S. National Institutes of Health (NIH), the AR1001 Phase 3 trial plan first registered in September 2022 had just one primary endpoint for determining success: the change in the Clinical Dementia Rating Sum of Boxes (CDR-SB) score in the “overall patient population.” However, on October 8, AriBio added the change in CDR-SB among the “monotherapy group” as a primary endpoint.


At the Clinical Trials on Alzheimer's Disease (CTAD 2026) conference held in Boston, United States, on the 17th (local time), Stanford University professor Sharon Sha presents the results of an analysis of Phase 3 clinical trials of AR1001, Aribio's investigational dementia treatment. Aribio

At the Clinical Trials on Alzheimer's Disease (CTAD 2026) conference held in Boston, United States, on the 17th (local time), Stanford University professor Sharon Sha presents the results of an analysis of Phase 3 clinical trials of AR1001, Aribio's investigational dementia treatment. Aribio

View original image

According to the company, the monotherapy group was added as a primary endpoint midway through last year, after patient enrollment had ended and one year before the 3.5-year trial was completed. Fred Kim, head of AriBio’s U.S. branch, said in a phone interview, “The monotherapy group was a subgroup defined in advance, before the trial began. Once patient enrollment was complete, we found that about 40% of the patients were receiving monotherapy, so we considered that significant and elevated it to a primary endpoint.” Asked why it took time for the change to appear on the registration site, he said, “It took time to discuss it with the FDA, the European Medicines Agency (EMA), and the Ministry of Food and Drug Safety.”


In principle, success criteria may be changed during a trial as long as the results are not known. The issue is that when a company announces success after lowering the bar, the FDA scrutinizes the process closely during its approval review. In its guidance for reviewers, the FDA says of changes to primary endpoints, “The later the timing and the greater the impact on the trial results, the greater the inevitable concern.” It also advises reviewers to verify that safeguards were robust enough to ensure that the people who decided to make the change could not access the clinical data accumulated up to that point.


Academics, too, urge caution about changing primary endpoints during a trial. In a 2007 paper, Scott Evans, director of the Biostatistics Center at George Washington University in the United States, noted that “changes to endpoints, particularly primary endpoints, should be rare.” He cited the difficulty of demonstrating that such a decision was not made after reviewing the data in advance.


[Exclusive] AriBio Adds 'Success Criterion' During Trial... "Discussed Thoroughly with FDA" View original image

“The FDA clearly points out disagreements... The clinical analysis plan was discussed thoroughly”


Kim said AriBio had consulted extensively with the FDA on elevating the monotherapy group to a primary endpoint. He said the two sides had established a close working relationship, holding at least four Type C meetings since the trial began. Type C meetings provide an opportunity to seek FDA advice on various issues in the new drug development process. The minutes serve as important reference material during the approval process, but do not guarantee a decision on approval.


“The FDA clearly says so when it disagrees, so we can say that we obtained its full agreement,” Kim said. “Since AR1001 was being tested in only one trial, we proposed several approaches at the time to increase the chances of success, and the FDA rejected 90% of them.” He said the FDA did not raise any objections to the final analysis plan, including the addition of the monotherapy group as a primary endpoint.


Since the Phase 3 results were announced, views have differed on the likelihood that AR1001 will be approved as a new drug. Some in the industry have cautiously suggested that approval may be difficult, given that all dementia treatments approved to date have demonstrated efficacy in the overall populations enrolled in their clinical trials.


Others believe the FDA could approve the drug, recognizing that it offers a new option with a mechanism of action different from existing treatments. At present, existing oral dementia drugs generally cannot be used during the early stage of dementia (mild cognitive impairment). The only treatment that can be used at this stage is an injectable drug that slows disease progression. However, patients must visit a hospital regularly to receive injections and undergo repeated brain scans to monitor for side effects. Kim Sang-yoon, a professor at Seoul National University Bundang Hospital who took part in the clinical trial, said, “If AR1001 is approved, it could become the first treatment option that early-stage patients in Korea can take at home.”



AriBio also maintains that it can make a strong case for approval of AR1001 as a new treatment for patients who are not taking existing dementia drugs, even though the eligible patient group is narrow. The company is also counting on the fact that the FDA gives significant consideration during its approval reviews to “unmet medical needs”—situations in which patients cannot receive proper treatment because no suitable treatment exists or because existing options lack sufficient efficacy, safety, or convenience.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing